阿达木单抗对非感染性小儿葡萄膜炎的疗效:对印度一家三级眼科医疗中心29只眼睛的分析。

IF 2.1 4区 医学 Q2 OPHTHALMOLOGY
Indian Journal of Ophthalmology Pub Date : 2024-12-01 Epub Date: 2024-07-11 DOI:10.4103/IJO.IJO_3223_23
Nida Khan, Parthopratim Dutta Majumder, Mahesh Janarthanan, Jyotirmay Biswas
{"title":"阿达木单抗对非感染性小儿葡萄膜炎的疗效:对印度一家三级眼科医疗中心29只眼睛的分析。","authors":"Nida Khan, Parthopratim Dutta Majumder, Mahesh Janarthanan, Jyotirmay Biswas","doi":"10.4103/IJO.IJO_3223_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To describe the treatment outcomes of adalimumab in noninfectious pediatric uveitis.</p><p><strong>Methods: </strong>The electronic medical records of children with noninfectious uveitis were reviewed retrospectively. The visual improvement and ocular inflammation were assessed according to the Standardization of Uveitis Nomenclature criteria before and after treatment with adalimumab.</p><p><strong>Results: </strong>Twenty-nine eyes of 16 patients were included. The mean age of children was 9.4 ± 3.8 years. There were eight (50%) males and eight (50%) females. Juvenile idiopathic arthritis was the most common cause of uveitis in these children (N = 10, 62.5%), followed by Behçet's disease (N = 3, 18.75%) and Vogt-Koyanagi-Harada disease (N = 2, 12.5%). One child (6.25%) was diagnosed with Crohn's disease. Nine (56.3%) children were previously treated with methotrexate, one each with mycophenolate mofetil (MMF) (6.3%), azathioprine (6.3%), and tofacitinib (6.3%), and one child received MMF followed by azathioprine and cyclosporine before shifting to adalimumab. Three (18.8%) children did not receive prior immunosuppressive therapy. The average number of adalimumab injections given was 20.3 ± 12.0 at an interval of 2 weeks. The mean follow-up duration was 22.2 ± 16.6 months. Disease inactivity was achieved in 28 (96.6%) eyes at last visit ( P < 0.001). The best-corrected visual acuity (BCVA) improved from 0.48 ± 0.6 logMAR (logarithm of minimum of resolution) units at baseline to 0.20 ± 0.2 logMAR units at last visit ( P = 0.018). Disease remission was achieved in 23 (79.3%) eyes at the third month ( P = 0.001).</p><p><strong>Conclusion: </strong>Adalimumab is effective in the treatment of pediatric noninfectious uveitis by achieving disease inactivity, reducing the recurrence rate and improving BCVA. The drug is safe and well tolerated.</p>","PeriodicalId":13329,"journal":{"name":"Indian Journal of Ophthalmology","volume":" ","pages":"1766-1771"},"PeriodicalIF":2.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of adalimumab in noninfectious pediatric uveitis: Analysis of 29 eyes from a tertiary eye care center in India.\",\"authors\":\"Nida Khan, Parthopratim Dutta Majumder, Mahesh Janarthanan, Jyotirmay Biswas\",\"doi\":\"10.4103/IJO.IJO_3223_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To describe the treatment outcomes of adalimumab in noninfectious pediatric uveitis.</p><p><strong>Methods: </strong>The electronic medical records of children with noninfectious uveitis were reviewed retrospectively. The visual improvement and ocular inflammation were assessed according to the Standardization of Uveitis Nomenclature criteria before and after treatment with adalimumab.</p><p><strong>Results: </strong>Twenty-nine eyes of 16 patients were included. The mean age of children was 9.4 ± 3.8 years. There were eight (50%) males and eight (50%) females. Juvenile idiopathic arthritis was the most common cause of uveitis in these children (N = 10, 62.5%), followed by Behçet's disease (N = 3, 18.75%) and Vogt-Koyanagi-Harada disease (N = 2, 12.5%). One child (6.25%) was diagnosed with Crohn's disease. Nine (56.3%) children were previously treated with methotrexate, one each with mycophenolate mofetil (MMF) (6.3%), azathioprine (6.3%), and tofacitinib (6.3%), and one child received MMF followed by azathioprine and cyclosporine before shifting to adalimumab. Three (18.8%) children did not receive prior immunosuppressive therapy. The average number of adalimumab injections given was 20.3 ± 12.0 at an interval of 2 weeks. The mean follow-up duration was 22.2 ± 16.6 months. Disease inactivity was achieved in 28 (96.6%) eyes at last visit ( P < 0.001). The best-corrected visual acuity (BCVA) improved from 0.48 ± 0.6 logMAR (logarithm of minimum of resolution) units at baseline to 0.20 ± 0.2 logMAR units at last visit ( P = 0.018). Disease remission was achieved in 23 (79.3%) eyes at the third month ( P = 0.001).</p><p><strong>Conclusion: </strong>Adalimumab is effective in the treatment of pediatric noninfectious uveitis by achieving disease inactivity, reducing the recurrence rate and improving BCVA. The drug is safe and well tolerated.</p>\",\"PeriodicalId\":13329,\"journal\":{\"name\":\"Indian Journal of Ophthalmology\",\"volume\":\" \",\"pages\":\"1766-1771\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/IJO.IJO_3223_23\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/IJO.IJO_3223_23","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:描述阿达木单抗在非感染性小儿葡萄膜炎中的治疗效果:方法:回顾性审查非感染性葡萄膜炎患儿的电子病历。方法:对非感染性葡萄膜炎患儿的电子病历进行回顾性审查,并根据葡萄膜炎命名标准化标准对阿达木单抗治疗前后的视力改善情况和眼部炎症情况进行评估:结果:共纳入16名患者的29只眼睛。患儿的平均年龄为(9.4 ± 3.8)岁。男性8名(50%),女性8名(50%)。幼年特发性关节炎是这些儿童葡萄膜炎最常见的病因(10 例,占 62.5%),其次是贝赫切特氏病(3 例,占 18.75%)和 Vogt-Koyanagi-Harada 病(2 例,占 12.5%)。一名儿童(6.25%)被诊断为克罗恩病。9名患儿(56.3%)曾接受过甲氨蝶呤治疗,1名患儿曾接受过霉酚酸酯(MMF)(6.3%)、硫唑嘌呤(6.3%)和托法替尼(6.3%)治疗,1名患儿在接受MMF治疗后又接受了硫唑嘌呤和环孢素治疗,之后才转为阿达木单抗治疗。3名患儿(18.8%)之前未接受过免疫抑制治疗。阿达木单抗的平均注射次数为20.3±12.0次,每次间隔2周。平均随访时间为(22.2 ± 16.6)个月。在最后一次就诊时,有28只眼睛(96.6%)达到了疾病活动期(P < 0.001)。最佳矫正视力(BCVA)从基线时的 0.48 ± 0.6 logMAR(最小分辨率对数)单位提高到最后一次就诊时的 0.20 ± 0.2 logMAR 单位(P = 0.018)。第三个月时,23 只眼睛(79.3%)的病情得到缓解(P = 0.001):结论:阿达木单抗治疗小儿非感染性葡萄膜炎效果显著,可达到疾病不活动、降低复发率和改善BCVA的目的。该药物安全且耐受性良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficacy of adalimumab in noninfectious pediatric uveitis: Analysis of 29 eyes from a tertiary eye care center in India.

Purpose: To describe the treatment outcomes of adalimumab in noninfectious pediatric uveitis.

Methods: The electronic medical records of children with noninfectious uveitis were reviewed retrospectively. The visual improvement and ocular inflammation were assessed according to the Standardization of Uveitis Nomenclature criteria before and after treatment with adalimumab.

Results: Twenty-nine eyes of 16 patients were included. The mean age of children was 9.4 ± 3.8 years. There were eight (50%) males and eight (50%) females. Juvenile idiopathic arthritis was the most common cause of uveitis in these children (N = 10, 62.5%), followed by Behçet's disease (N = 3, 18.75%) and Vogt-Koyanagi-Harada disease (N = 2, 12.5%). One child (6.25%) was diagnosed with Crohn's disease. Nine (56.3%) children were previously treated with methotrexate, one each with mycophenolate mofetil (MMF) (6.3%), azathioprine (6.3%), and tofacitinib (6.3%), and one child received MMF followed by azathioprine and cyclosporine before shifting to adalimumab. Three (18.8%) children did not receive prior immunosuppressive therapy. The average number of adalimumab injections given was 20.3 ± 12.0 at an interval of 2 weeks. The mean follow-up duration was 22.2 ± 16.6 months. Disease inactivity was achieved in 28 (96.6%) eyes at last visit ( P < 0.001). The best-corrected visual acuity (BCVA) improved from 0.48 ± 0.6 logMAR (logarithm of minimum of resolution) units at baseline to 0.20 ± 0.2 logMAR units at last visit ( P = 0.018). Disease remission was achieved in 23 (79.3%) eyes at the third month ( P = 0.001).

Conclusion: Adalimumab is effective in the treatment of pediatric noninfectious uveitis by achieving disease inactivity, reducing the recurrence rate and improving BCVA. The drug is safe and well tolerated.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.80
自引率
19.40%
发文量
1963
审稿时长
38 weeks
期刊介绍: Indian Journal of Ophthalmology covers clinical, experimental, basic science research and translational research studies related to medical, ethical and social issues in field of ophthalmology and vision science. Articles with clinical interest and implications will be given preference.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信